BioVie Announces Bezisterim Has Potential To Treat Parkinson's Disease; To Hold Talks With FDA Over Phase 3 Trial Design
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced next stage of
BioVie is working on a medicine that might help people with Parkinson's disease and plans to talk with the FDA about testing it on more patients. This shows the company is moving forward, but it's still early and testing hasn't proven it works yet.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.